MAP
DAWN

Moody Aldrich Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Moody Aldrich Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-117,326
Closed -$1.57M – 162
2023
Q1 		$1.57M Buy
+117,326
New +$2.29M 0.32% 101

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Moody Aldrich Partners's DAWN Position: Q2 2023 in Review

Moody Aldrich Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2023, closing a stake of 117,326 shares — an estimated $1.57M sold.

Moody Aldrich Partners first reported a position in DAWN in Q1 2023 and held it in 1 quarter. The position peaked at $1.57M in Q1 2023. 140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • Moody Aldrich Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Moody Aldrich Partners sold 117,326 Day One Biopharmaceuticals shares in Q2 2023, an estimated $1.57M.
  • Moody Aldrich Partners first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Moody Aldrich Partners's Day One Biopharmaceuticals position peaked at $1.57M in Q1 2023.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on Moody Aldrich Partners's 13F filing for Q2 2023, filed 28 Jul 2023.